Supplement

	No.		Proportion	9
study	pts		(95% CI)	Weigh
Arnold	110	-	0.05 (0.02, 0.10)	8.7
Banda	107	*	0.06 (0.03, 0.12)	8.6
Carfi	143		0.27 (0.21, 0.35)	8.18
Carvalho	150		0.09 (0.05, 0.14)	8.63
Cellai	26		0.31 (0.17, 0.50)	5.79
Cirulli	233		0.03 (0.01, 0.06)	8.8
Galal	370	-	• 0.57 (0.52, 0.62)	8.56
Goertz	2113	-	0.22 (0.20, 0.24)	8.8
Huang	1655		0.09 (0.08, 0.11)	8.90
Jacobs	183	-	0.16 (0.11, 0.22)	8.52
Kamal	287		0.31 (0.26, 0.37)	8.5
Taboada	91		0.29 (0.20, 0.39)	7.78
Overall, DL	(l ² = 98.3%, p = 0.000)	$\langle \rangle$	0.20 (0.13, 0.27)	100.00

Figure S1. Pooled estimate of the prevalence of joint pain in patients with long COVID-19

	No.		Proportion	9
study	pts		(95% CI)	Weigh
Arnold	110		0.12 (0.07, 0.19)	7.34
Banda	107		0.09 (0.05, 0.16)	7.4
Cellai	26		• 0.54 (0.35, 0.71)	4.7
Chopra	488	-	0.15 (0.12, 0.19)	7.67
Cirulli	233	-	0.13 (0.09, 0.18)	7.50
Daher	33		0.33 (0.20, 0.50)	5.39
Galal	370	-	0.29 (0.25, 0.34)	7.52
Garriges	120		0.17 (0.11, 0.24)	7.25
Goertz	2113	•	0.29 (0.27, 0.31)	7.75
Jacobs	183		0.25 (0.19, 0.32)	7.30
Moreno	277		0.21 (0.17, 0.26)	7.50
Poyraz	118	•	0.02 (0.00, 0.06)	7.73
Taboada	91	-	0.14 (0.09, 0.23)	7.1
Zhao	55	•	0.02 (0.00, 0.10)	7.64
Overall, DL	(l ² = 97.1%, p = 0.000)		0.18 (0.12, 0.25)	100.00

Figure S2. Pooled estimate of the prevalence of cough in patients with long COVID-19

study	No. pts		Proportion (95% CI)	% Weight
	·			
Arnold	110	-	0.02 (0.01, 0.06)	7.47
Banda	107	-	0.07 (0.03, 0.13)	7.36
Cellai	26		0.50 (0.32, 0.68)	5.57
Cirulli	233	*	0.07 (0.04, 0.11)	7.44
Daher	33		0.15 (0.07, 0.31)	6.59
Galal	370	-	0.40 (0.35, 0.45)	7.34
Goertz	2113	•	0.38 (0.36, 0.40)	7.48
Huang	1655	•	0.02 (0.01, 0.03)	7.5
Jacobs	183		0.13 (0.09, 0.18)	7.3
Kamal	287	-	0.29 (0.24, 0.34)	7.32
Moreno	277	*	0.18 (0.14, 0.23)	7.3
Poyraz	118		0.17 (0.11, 0.25)	7.20
Yiping	60	-	0.10 (0.05, 0.20)	7.13
Zhao	55	-	0.18 (0.10, 0.30)	6.84
Overall, DL	. (l ² = 99.1%, p = 0.000)		0.18 (0.09, 0.27)	100.00

Figure S3. Pooled estimate of the prevalence of headache in patients with long COVID-19




Figure S4. Pooled estimate of the prevalence of chest pain in patients with long COVID-19

study	No. pts		Proportion (95% CI)	Weigh
			· · ·	
Arnold	110		0.12 (0.07, 0.19)	6.7
Banda	107	•	0.02 (0.01, 0.07)	8.2
Carvalho	150		0.27 (0.20, 0.34)	6.2
Cellai	26		0.31 (0.17, 0.50)	2.5
Cirulli	233	-	0.10 (0.07, 0.15)	7.7
Daher	33		0.12 (0.05, 0.27)	4.43
Garriges	120		0.13 (0.08, 0.21)	6.7
Goertz	2113	•	0.13 (0.12, 0.15)	8.5
Huang	1655		0.11 (0.09, 0.12)	8.5
Jacobs	183		0.09 (0.06, 0.14)	7.6
Moreno	277		0.21 (0.17, 0.26)	7.3
Otte	91	-	• 0.46 (0.36, 0.56)	4.7
Poyraz	118		0.17 (0.11, 0.25)	6.4
Taboada	91		0.11 (0.06, 0.19)	6.5
Yiping	60	•	0.03 (0.01, 0.11)	7.4
Overall, DL	(l ² = 91.1%, p = 0.000)	\land	0.14 (0.11, 0.18)	100.0

Figure S5. Pooled estimate of the prevalence of altered smell in patients with long COVID-19




Figure S6. Pooled estimate of the prevalence of altered taste in patients with long COVID-19




Figure S7. Pooled estimate of the prevalence of diarrhoea in patients with long COVID-19